Trial document

drksid header


Trial Description

start of 1:1-Block title


Comparison of a conventional non-invasive ventilation to a non-invasive pursed-lip breathing ventilation (PLBV) ventilation in advanced COPD

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language


end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Pursed-lip breathing is a breathing technique that results in improved pulmonary deflation and reduction of trapped air volume. It requires active and conscious ventilation, therefore it cannot be performed when sleeping. The non-invasive ventilator FLO Vigaro (manufacturer: FLO Medizintechnik GmbH, 49328 Melle, Germany) is the first device with an integrated pursed-lip breathing ventilation mode (PLBV) facilitating the build-up of a dynamic positive pressure during expiration.
It can be assumed that implementing PLBV in patients with advanced COPD results in normalisation of ventilatory function with subsequent improved oxygenation, reduced hypercapnia and better exercise capacity. Reduced collapse of the small airways, fewer dystelectases and more effective mucus clearance can potentially reduce pulmonary dysbiosis and exacerbation rates. Subsequently, quality of life, number of hospital admissions, healthcare related costs and mortality rates may improve. In contrast to active pursed-lip breathing, the beneficial effects of PLBV may be achieved from nocturnal ventilation.
The most established surrogate marker for alveolar ventilation, capillary pCO2 is expected to drop in hypercapnic patients and remain within normal range in normocapnic patients. Due to normalised ventilation mechanics, these clinical and biochemical effects can be achieved with significantly lower inspiratory ventilation pressures, improving the patient’s compliance In contrast to conventional ventilation modes, PLBV does not apply a fixed positive pressure in expiration but adjusts airway resistance to the airflow. The dynamic pressure that is added to a constant PEEP can be adjusted as required. Thereby, PLBV augments the reduction of Auto-PEEP phenomena and improves pulmonary deflation.
This prospective, multicentre study aims to evaluate this ventilation mode in patients with severe COPD and pre-existing NIV ventilation. Patients in the control group keep their NIV device, patients in the intervention group will be treated with the new VIGARO NIV device in PLBV mode. The treatment duration is 3 months, followed by a 9 months follow-up period.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00012325
  •   2017/08/14
  •   [---]*
  •   yes
  •   Approved
  •   17-127, Ethik-Kommission Universität zu Lübeck Medizinische Fakultät des Universitätsklinikums Schleswig-Holstein
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   COPD
  •   J44.9 -  Chronic obstructive pulmonary disease, unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Treatment with pursed lip breathing ventilation NIV for 3 months (Vigaro NIV device)
  •   Treatment with standard NIV (Non-invasive Ventilation)
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Distance of the 6 minute walk test at 3 months

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

At 3 months therapy: NIV parameters (IPAP, PEEP), blood gas analysis (pCO2), number of hospital admissions

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
  • Medical Center 
  • University Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2018/02/26
  •   256
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   40   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Age >40 years
2. COPD diagnosis known for at least 12 months
3. NIV therapy for at least 3 months
4. Regular use of NIV with extrapolated usage time of at least 700 hours / year
5. Current inspiratory NIV pressure ≥20 mbar
6. Patient understands the requirements of the study
7. Patient is able to follow the study protocol

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1.Current COPD exacerbation (is allowed 4 weeks after end of treatment)
2.Radiologically proven pneumonia within the past month
3.Other leading pulmonary illness
6.Pregnancy or lactation
7.BMI >35 kg/m²
8.Steroid therapy with >15 mg prednisolon daily for >1 month
9.Condition causing hypercapnia other than COPD
10.6MWT distance of >300 meters within the last 7 days
11.Previous therapy with the Vigaro NIV device
12.Weight loss of more than 5 kg / 12 months
13.Further criteria to exclude confounding factors

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Forschungszentrum Borstel
    • Parkallee 1-40
    • 23845  Borstel
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Forschungszentrum Borstel
    • Mr.  Dr. med.  Christian  Herzmann 
    • Parkallee 35
    • 23845  Borstel
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Forschungszentrum BorstelKlinisches Studienzentrum
    • Ms.  Vanessa  Schümann 
    • Parkallee 35
    • 23845  Borstel
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsches Zentrum für Lungenforschung, e.V.
    • Aulweg 130
    • 35392  Gießen
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.